Role of tumour markers in monitoring epithelial ovarian cancer by Meyer, T & Rustin, G J S
A wide variety of tumour markers are now available to the
clinician caring for patients with malignant disease. They have the
potential to contribute to screening, diagnosis and prognosis, as
well as providing a means of monitoring response to treatment or
indicating relapse during follow-up. Some may also provide
specific targets for anti-tumour therapy with antibody-directed
treatments or gene therapy. In the majority of cases, however, the
role of tumour markers in patient management remains to be fully
defined and many markers suffer from poor specificity and/or
sensitivity.
In epithelial ovarian carcinoma a number of tumour markers
have been identified. The most extensively researched is CA125, a
large glycoprotein of unknown function. In addition, several
epitopes on the polymorphic epithelial mucin derived from the
MUC1 gene have been identified as targets for a family of tumour
markers which include CA549, CASA (cancer associated serum
antigen), CA19-9, CA15-3, MCA, MOV-1 and TAG72 (Ward,
1994). The cytokeratin proliferation markers TPS and CYFRA21-
1 have also been explored in ovarian carcinoma as have enzymes
such as placental alkaline phosphatase and biological markers
such as CSF and inhibin. In most cases the assays for these
markers are not widely available and their relevance to the
management of ovarian carcinoma remains to be determined. The
exception is CA125 which has been sufficiently well validated to
be of use in routine clinical care. For this reason the bulk of the
following review will focus on the uses and limitations of CA125
in managing ovarian cancer and the possible contribution of other
markers will be discussed where relevant.
CA125
The CA125 antigen was originally identified following the devel-
opment of the OC125 antibody, raised by injecting an ovarian
cancer cell-line into mice (Bast et al, 1981). The antigen is a
200 000 MW glycoprotein with mainly N-linked glycosylation
and is distributed on the endothelium of fallopian tubes,
endometrium, endocervix, and also in the normal ovary. In
addition, it is found on the mesothelial cells of the pleura, peri-
cardium and peritoneum. The serum concentration of CA125 is
elevated by the vascular invasion, tissue destruction and inflam-
mation associated with malignant disease and is elevated in over
90% of those women with advanced ovarian cancer (Tuxen et al,
1995) and 40% of all patients with advanced intra-abdominal
malignancy. Levels can also be elevated during menstruation or
pregnancy and in other benign conditions such as endometriosis,
peritonitis or cirrhosis, particularly with ascites.
Screening
The 5-year survival rate for those with stage I carcinoma of the
ovary is around 85% but less than 25% of women present with
stage I disease. For the 60% of women that present with stage III
or stage IV disease the survival rate drops to less than 20%.
Screening, therefore, has the theoretical appeal of improving
survival by diagnosing ovarian cancer at a less advanced stage. To
date, no randomized trials of ovarian cancer screening have been
reported to have a significant impact on the natural history of the
disease.
Several studies have examined CA125 as a potential screening
tool to assess its feasibility, sensitivity and specificity (Einhorn et
al, 1992; Jacobs et al, 1993; 1988; Skates et al, 1995). In a study of
22 000 postmenopausal women, the combination of CA125 with
ultrasound achieved a sensitivity for detecting ovarian cancer of
79% at 1-year follow-up. However, the sensitivity of CA125 to
detect stage I carcinoma of the ovary is only about 50% (Jacobs
et al, 1993) which limits its value as an initial screening tool since
picking up stage III disease at an earlier time may not alter
outcome. A greater sensitivity for detecting earlier disease has
been achieved using a combination of markers and in one study in
which CA125, OVX1 and M-CSF were used, 98% of women with
stage I ovarian carcinoma had elevated levels of one or more.
Unfortunately, specificity is compromised and 11% of healthy
women and 51% of women with benign disease also had elevated
levels (Woolas et al, 1993). Nevertheless, a large randomized
study to assess the feasibility of population screening using
CA125 values alone has recently been reported (Jacobs et al,
1999). 21 935 postmenopausal women over the age of 45 were
randomized into a control group or a 3-year screening programme.
Screening consisted of an annual CA125 measurement which, if
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on ultrasound, the volume of the ovary was greater than 8.8 ml, a
gynaecological referral was made. The compliance rate was high
with 70.7% completing the 3-year screening programme. Of the
10 958 women entering the screening arm 468 (4.3%) had a raised
CA125, 29 (0.26%) had surgical investigation and six (0.055%)
had screen-detected ovarian cancer of which three had potentially
curable stage I or II disease (Jacobs et al, 1999). The positive
predictive value of the screening strategy was 21% but the trial
was insufficiently large to detect significant differences in
mortality.
Further studies with larger numbers of women must be under-
taken to establish if there is any real benefit in terms of survival
and to address the psychosocial and health economic issues raised
by such a programme. Apart from women at high risk, who may be
eligible for the ongoing UKCCR trial, ovarian cancer screening
with CA125 is not currently recommended (Department of Health,
1999).
Diagnosis
No single marker has been shown to be sufficiently sensitive or
specific to contribute to the diagnosis of ovarian cancer. For
example, CA125 levels above 35 U ml–1 will be found in 1% of the
normal population, 6% of patients with benign disease, 28% of
individuals with non-gynaecological malignancy and 82% of
patients with epithelial ovarian cancer (Bast et al, 1983). The level
of CA125 taken in conjunction with pelvic ultrasound and
menopausal status may help further to distinguish benign from
malignant disease (Jacobs et al, 1990). Combinations of markers
may be of value and a sensitivity of 73% and specificity of 100%
has recently been reported using the combination of CA125 and
D-dimer analysis in a series of 56 women with epithelial ovarian
cancer and 65 with benign ovarian disease (Gadducci et al, 1996).
In another study the combination of five different tumour markers
(CA125, OVX1, LASA, CA15-3 and CA72-4) achieved a speci-
ficity of 93% and a sensitivity of 90.6% in differentiating benign
from malignant disease using logistic regression analysis (Woolas
et al, 1995). In practice, however, the diagnosis will follow surgery
and histological evaluation in the majority of cases, and tumour
markers are unlikely to contribute.
During initial management
Levels of CA125 may be elevated by tissue damage for 2 weeks
following surgery and residual disease should be suspected if
levels plateau above the upper limit of normal or rise after this
interval. With a half-life of 6 days, CA125 may take many weeks
to return to normal after surgery. Thus, unless a pre-chemotherapy
level is the same or higher than a previous sample taken after
surgery, any subsequent fall would be due to surgery and/or
chemotherapy. Conversely, a rising CA125 level may indicate
progressive disease in the 20% of women who do progress during
their initial treatment. Earlier detection of progressive disease
could spare the patient further ineffective treatment and consider-
able savings can be made in terms of therapy and investigations
(Rustin et al, 1992). Criteria for progression need to be defined if it
is to be relied upon as a single indicator of treatment failure. Such
analysis must be highly specific in order that effective treatment is
not stopped prematurely and any consequent loss of sensitivity
means that progressing patients would be picked up by conven-
tional clinical means rather than CA125. Using a rise of 25% in the
CA125, confirmed by a third sample, has been shown to yield a
specificity of 100% and a sensitivity of 40% (Rustin et al, 1992).
During routine follow-up
In about 70% of patients a rising CA125 may be the first indication
of relapse, predating clinical relapse by a median of 4 months
(Rustin et al, 1996b; van der Burg et al, 1990). Furthermore, since
performance status, tumour bulk and number of tumour lesions are
independent prognostic factors for response, progression-free and
overall survival, one might speculate that earlier detection of
relapse would be beneficial (Eisenhauer et al, 1997). However, the
value of routinely measuring CA125 during the follow-up of
women after initial treatment is uncertain and practice varies.
Some clinicians routinely perform CA125 measurements and treat
asymptomatic patients on the basis of a rising level alone, while
others ignore a rising level until symptoms warrant treatment or do
not measure CA125 at all. It must be remembered that relapse after
initial treatment is usually incurable and any theoretical advantage
of instituting palliative chemotherapy at an earlier stage must be
weighed against the anxiety, regular venepuncture and loss of
treatment-free time which arises as a consequence of such moni-
toring. The impact of such monitoring on overall survival,
symptom-free survival and quality of life is currently being
assessed in a multicentre MRC/EORTC trail in which patients who
are in remission following initial treatment are randomized
between immediate treatment (within 4 weeks) of relapse by
CA125 criteria or treatment only on clinical relapse.
Until the results of this trial are known, CA125 should not be
routinely monitored and its measurement should be reserved as an
aid to the diagnosis of relapse when clinically suspected.
Defining relapse during follow-up by CA125
If CA125 is to be relied upon as an indicator of relapse in the
absence of disease evaluable by other methods, it must be suffi-
ciently sensitive to reliably confirm clinically-suspected relapse or
demonstrate progressive disease on treatment. Moreover, it should
be highly specific in order that effective therapy is not stopped
prematurely on account of a false-positive result.
A rise of 50% (Krebs et al, 1986) or 100% (Bast et al, 1983) has
been shown to be predictive of progression and in one study a level
of CA125 above the normal range was found in 73% of relapsed
patients (van der Burg et al, 1990). In this study the addition of
physical and gynaecological examination increased the detection
of relapse up to 92%, so that the addition of radiological investiga-
tions or surgery only contributed to the diagnosis in 8% of cases
(van der Burg et al, 1990).
Several studies have analysed definitions of progression
according to CA125. In one such study of 255 patients following
initial chemotherapy, a doubling of CA125 above the upper limit
of normal was found to have a sensitivity of 85.9%, a specificity of
91.3% and a positive predictive value of 94.8% for indicating
progression. The addition of a confirmatory raised level reduced
the false-positive rate to 2% and progression by these criteria
provided a median lead time of 63 days over standard clinical
criteria (Rustin et al, 1996b). This definition has been adopted for
the MRC/EORTC CA125 follow-up trial discussed above. Clearly
these data suggest that CA125 is able to reliably indicate relapse
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relapse, is frequently used to instigate further chemotherapy.
The use of CA125 as a marker of response to therapy
Many patients with advanced ovarian carcinoma are ineligible for
clinical trials because their disease is not evaluable according to
the standard response criteria as defined by the World Health
Organisation (WHO), the Gynaecology Oncology Group (GOG)
or the Eastern Cooperative Oncology Group (ECOG) (Blessing,
1990; Miller et al, 1981; Oken et al, 1982). Defining response
according to CA125, which is elevated in 95% of women with
advanced disease, therefore presents the possibility of entering
more women into clinical trails, as well as obviating the need for
intensive radiological investigation. Several definitions have been
proposed (Markman, 1993; Ng et al, 1989; Rustin et al, 1993) but
the only definition that has been validated prospectively is that of
Rustin (Rustin et al, 1996a). In this study, CA125 response criteria
were generated by examining data from 277 patients participating
in the North Thames Ovary trial of maintenance radiotherapy
versus carboplatin. A biological response was scored for an indi-
vidual patient if there was either a 50% or 75% decrease in CA125
levels calculated according to mathematical logic by a computer
program, to avoid mistakes and to provide the precision required
by clinical trials (Rustin et al, 1996a; Rustin et al, 1999). A 50%
response was defined as a 50% decrease in the CA125 level
following two levels which were elevated, and this decrease was
confirmed by a fourth sample. A 75% response occurred if there
was a fall in the value of the CA125 by 75% over three samples. In
each case the final sample had to be analysed at least 28 days from
the preceding sample. These response definitions were then tested
in two other groups of patients; 254 from the North Thames Ovary
five versus eight trial and 458 from the GOG dose-intense versus
standard chemotherapy trail. Of the 620 patients that were assess-
able for response according to CA125 only two (0.3%) had a
CA125 response at the time of clinical progression. In the GOG
trial, CA125 response was 66% in all 317 patients assessable for
CA125 and 67% in 221 patients who were not measurable
according to GOG criteria. This compares with a GOG-defined
response rate of 62%. Thus using these criteria CA125 can be used
to accurately determine response rates to first-line chemotherapy.
Subsequently, these CA125 response definitions have been
validated in a large number of clinical trials including drugs such
as cisplatin and paclitaxel (Bridgewater et al, 1999). A recent
analysis of 1396 patients involved in the testing of 14 investiga-
tional drugs for relapsed ovarian cancer in phase II clinical trials
found that CA125 response rates concurred with standard response
rates and could therefore provide a reliable, cheaper and more
available means of identifying active drugs worthy of further study
(Rustin et al, 2000).
For managing the individual patient many factors are considered
when deciding whether or not to continue with therapy and the rise
or fall of the CA125 can make a useful contribution. Caution is
needed since levels in the individual undergo random fluctuation
and can fall in response to the drainage of malignant effusions or
ascites. Some authors have raised concerns that specific drugs
such as paclitaxel may render CA125 levels unreliable (Davelaar
et al, 1996; Pearl et al, 1994) for indicating response. This question
has recently been re-examined in 144 patients treated with
paclitaxel in four different trials using the 50% and 75% response
criteria defined above (Bridgewater et al, 1999). The progression-
free survival for responders compared with non-responders was
equivalent regardless of whether CA125 or standard response
criteria were used. Furthermore, the false-positive rate for a
CA125 response was less than 3% suggesting that, if the CA125
suggests a response, then there is a response in 97% of cases
and radiological reassessment is probably not warranted. False-
negative rates, however, were higher at about 21% and stopping
treatment on the basis of absence of response according to CA125
alone would therefore risk under-treating patients. Such under-
treatment could be avoided if therapy were continued until there
was evidence of progression by clinical, radiological or CA125
criteria (Rustin et al, 1999).
Prognosis
The value of tumour markers as indicators of prognosis has been
explored both at diagnosis and during initial treatment.
Studies examining the prognostic implications of preoperative
CA125 have been contradictory (Tuxen et al, 1995) and many
investigators have found CA125 to be of no prognostic value
(Sevelda et al, 1989; van der Burg et al, 1988). However, in one
study of 201 patients with stage I disease, CA125 emerged as a
powerful prognostic factor for survival by multivariate analysis
(Nagele et al, 1995). Those women with a CA125 above 65 U ml–1
had a 6.37-fold risk of dying from disease compared to those with
levels below this cut-off. With current practice of giving adjuvant
chemotherapy for stage IC disease and above, the identification of
other high-risk stage I patients may be of clinical value. Other
markers may emerge as of greater prognostic significance than
CA125 and in one recent preliminary report, CA125 was
compared with serum levels of the soluble urokinase-type plas-
minogen activator receptor (suPAR). While CA125 was found to
be a more specific marker of ovarian cancer than suPAR, high
preoperative levels of suPAR were associated with a worse
survival, whereas CA125 was found to have no prognostic
significance (Seir et al, 1998).
Several studies have examined CA125 as a prognostic tool
during initial chemotherapy and again its use in this setting is
limited. Initial small studies suggested that the half-life (van der
Burg et al, 1988) or regression parameter for CA125 (Buller et al,
1992) in an individual could be used to divide patients into better
or worse prognostic groups, while in other studies the division was
made using an optimum cut-off for the CA125 value after one, two
or three courses of chemotherapy (Lavin et al, 1987; Sevelda et al,
1989). A larger study subsequently re-evaluated several of these
methods in a patient group of 248 and found that the best predic-
tive measurement was the value of the CA125 prior to the third
course of treatment (Fayers et al, 1993). Using a cut-off of 70 IU
ml–1, 57% with a level above this were correctly predicted to
progress or die within 12 months while 80% of those with a level
below 70 IU ml–1 were alive and progression-free. However, this
still means that 43% patients with a CA125 above 70 after two
courses of treatment were alive and well at 12 months. A decision
to abandon further treatment at that stage or give more aggressive
treatment may well have been misguided. The authors conse-
quently conclude that the prognostic information gained from
CA125 alone is not sufficiently accurate to manage individual
patients during initial chemotherapy.
This view is supported by the work of Peters-Engl et al reported
in this journal. In this study a regression parameter was defined
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months postoperatively after two cycles of chemotherapy. This
parameter proved to be a significant prognostic factor during the
first 12 months, but thereafter it failed to discriminate between
long- or short-term survivors. Nevertheless, although CA125 may
be a poor predictor of long-term prognosis, it is accurate at indi-
cating actual tumour progression. Again, there has been some
interest in whether combinations of tumour markers may be of
value in improving the detection of residual disease during initial
treatment. Elevated OVX1 levels have been found in 70% of
patients with carcinoma of the ovary but only 5% of the normal
population. When used in combination with CA125 in patients
undergoing second-look surgery, 56% of women were correctly
identified as having residual disease compared with 35% using CA
125 alone (Xu et al, 1993).
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